Log In
BCIQ
Print this Print this
 

nesvacumab (REGN910, SAR307746)

  Manage Alerts
Collapse Summary General Information
Company Regeneron Pharmaceuticals Inc.
Description mAb against angiopoietin 2 (ANG2; ANGPT2)
Molecular Target Angiopoietin 2 (ANG2) (ANGPT2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$65.0M

$20.0M

$45.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/06/2013

$65.0M

$20.0M

$45.0M

Get a free BioCentury trial today